|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||599.00 - 613.50|
|52 Week Range||480.20 - 663.40|
|PE Ratio (TTM)||42.34|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
When Cipla Limited (NSEI:CIPLA) released its most recent earnings update (30 September 2017), I wanted to understand how these figures stacked up against its past performance. The two benchmarks IRead More...
Stocks with market capitalization between $2B and $10B, such as Cipla Limited (NSEI:CIPLA) with a size of ₹476.25B, do not attract as much attention from the investing community as doRead More...
(Reuters) - Indian private sector lenders Yes Bank Ltd and IndusInd Bank Ltd will join the BSE stock exchange's 30-member Sensex index, effective Dec. 18, the index provider said on Friday. Drugmakers ...
(Reuters) - Cipla Ltd, India's second largest drugmaker by market capitalisation, posted its second straight rise in quarterly profit, slightly above analysts' estimate, boosted by strong domestic sales. ...
To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/Indiamorning/MNC_IN_08142017.pdf If you would like to receive this newsletter via email, please register ...
Indian drugmaker Cipla Ltd's third-quarter profit beat estimates due to higher sales in the United States, and the company said it was looking for licensing deals and acquisitions to build its speciality medicines pipeline in that market. The country's fifth-largest drugmaker by sales reported a roughly 21 percent rise in revenue from North America for the October-December period. Cipla bought two U.S. generic drug producers, Invagen and Exelan, for about $550 million last year in its first big move to expand in a market where most of its local peers already have a large presence.